Page 32 - Read Online

Page 16 of 16 Cidon. J Unexplored Med Data 2018;3:8 I http://dx.doi.org/10.20517/2572-8180.2018.03

phase II-trial. Cancer Immunol Immunother 1992;35:325-30.
51. Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, et al. Efficiency of adjuvant active specific immunization with
newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective
randomized trial. Cancer Immunol Immunother 2009;58:61-9.
52. Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res 2017;27:74-95.
53. Sabado RL, Meseck M, Bhardwaj N. Dendritic cell vaccines. Methods Mol Biol 2016;1403:763-77.
54. Fong L, Hou Y, Rivas A, Benike C, Yuen A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor
immunotherapy. Proc Natl Acad Sci U S A 2001;98:8809-14.
55. Caballero-Baños M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, et al. Phase II randomised trial of autologous tumour lysate dendritic
cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. Eur J Cancer
2016;64:167-74.
56. Shimodaira S, Sano K, Hirabayashi K, Koya T, Higuchi Y, et al. Dendritic cell-based adjuvant vaccination targeting wilms’ tumor 1 in
patients with advanced colorectal cancer. Vaccines (Basel) 2015;3:1004-18.
57. Lazoura E, Apostolopoulos V. Rational peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem
2005;12:629-39.
58. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 2002;20:2197-207.
59. Ahsan A, Ramanand SG, Bergin IL, Zhao L, Whitehead CE, et al. Efficacy of an EGFR-specific peptide against EGFR-dependent cancer
cell lines and tumor xenografts. Neoplasia 2014;16:105-14.
60. Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, et al. MUC1 vaccine for individuals with advanced adenoma of the colon:
a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 2013;6:18-26.
61. Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, et al. Induction of cellular immune responses to tumor cells and peptides in colorectal
cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001;7:3950-62.
62. Okuno K, Sugiura F, Inoue K, Sukegawa Y. Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for patients with
metastatic colorectal cancer. Anticancer Res 2014;34:3045-52.
63. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, et al. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio
predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009;137:1270-9.
64. Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-
TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor,
in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005;23:720-31.
65. Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with
metastatic colorectal cancer. Clin Cancer Res 2008;14:4843-9.
66. Rowe J, Cen P. TroVax in colorectal cancer. Hum Vaccin Immunother 2014;10:3196-200.
67. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, et al. Talimogene laherparepvec improves durable response rate in
patients with advanced melanoma. J Clin Oncol 2015;33:2780-8.
68. Coffin R. Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer.
Immunotherapy 2016;8:103-6.
69. Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, et al. Oncolytic viral therapy for human colorectal cancer and liver
metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999;13:1325-34.
70. Geevarghese SK, Geller DA, de Haan HA, Hörer M, Knoll AE, et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in
patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 2010;21:1119-28.
71. Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, et al. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer
2016;52:50-66.
72. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell
function to promote tumoral immune escape. Cancer Res 2012;72:917-27.
73. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.
Genes Chromosomes Cancer 2011;50:307-12.
74. Posey AD Jr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, et al. Engineered CAR T cells targeting the cancer-associated Tn-
glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 2016;44:1444-54.
75. Chmielewski M, Rappl G, Hombach AA, Abken H. T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-
specific tumour protection in the long term. Gene Ther 2013;20:177-86.
76. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, et al. T cells targeting carcinoembryonic antigen can mediate regression of
metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011;19:620-6.